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Abstract
Objective: Currently, there is no effective medical treatment for patients with pituitary-dependent
Cushing’s disease. A novel somatostatin (SS) analogue, named SOM230, with high binding affinity
to SS receptor subtypes sst1, sst2, sst3 and sst5 was recently introduced. We compared the in vitro
effects of the sst2-preferring SS analogue octreotide (OCT) and the multi-ligand SOM230 on ACTH
release by human and mouse corticotroph tumour cells.
Methods: By quantitative RT-PCR the sst subtype expression level was determined in human cortico-
troph adenomas. In vitro, the inhibitory effect of OCT and SOM230 on ACTH release by dispersed
human corticotroph adenoma cells and mouse AtT20 corticotroph adenoma cells was determined.
In addition, the influence of dexamethasone on the responsiveness to OCT and SOM230 was studied.
Results: Corticotroph adenomas expressed predominantly sst5 mRNA (six out of six adenomas),
whereas sst2 mRNA expression was detected at significantly lower levels. In a 72 h incubation
with 10 nmol/l SOM230, ACTH release was inhibited in three out of five cultures (range 230 to
240%). Ten nmol/l OCT slightly inhibited ACTH release in only one of five cultures (228%). In
AtT20 cells, expressing sst2, sst3 and sst5, SOM230 inhibited ACTH secretion with high potency
(IC50 0.2 nmol/l). Dexamethasone (10 nmol/l) pre-treatment did not influence the sensitivity of the
cells to the inhibitory effect of SOM230, suggesting that sst5 is relatively resistant to negative control
by glucocorticoids.
Conclusions: The selective expression of sst5 receptors in corticotroph adenomas and the preferential
inhibition of ACTH release by human corticotroph adenoma cells by SOM230 in vitro, suggest that
SOM230 may have potential in the treatment of patients with pituitary-dependent Cushing’s disease.
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Introduction
The first choice of treatment of patients with pituitary-
dependent Cushing’s disease is surgery. If surgery fails,
radiotherapy, alone or in combination with steroido-
genic inhibitors, may be used (1, 2). These secondary
options are primarily due to the absence of an effective
medical treatment option (3, 4). Some preliminary data
suggest a potential use of dopamine agonists, alone or
in combination with ketoconazole, in selected cases of
Cushing’s disease or Nelson’s syndrome (2). The
expression of somatostatin (SS) receptors (sst) in adre-
nocorticotrophin (ACTH)-secreting pituitary adenomas
has been studied in vivo and in vitro. In vivo, none of a
series of eight corticotroph microadenomas showed
an increased uptake of 111In-DTPA-labelled octreotide
(OCT), whereas sst scintigraphy was positive in two
invasive ACTH-secreting macroadenomas and two
cases of Nelson’s tumours (5). The current generation
of sst2-preferential SS analogues have no suppressive
effect on ACTH level in patients with untreated Cush-
ing’s disease, who have elevated cortisol levels (6).
However, the SS analogue OCT suppressed pathological
ACTH release in patients with Nelson’s syndrome and
ACTH and cortisol secretion in patients with Cushing’s
syndrome caused by ectopic ACTH secretion (7–9).
Overall, these data suggest that in corticotroph adeno-
mas of untreated patients with Cushing’s disease levels
of sst2, one of the five known sst subtypes to which OCT
binds preferentially, are low, and that this receptor
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subtype may be downregulated when circulating corti-
sol levels are high. The fact that ectopic ACTH-secreting
tumours express sufficient sst numbers allowing their in
vivo visualization by sst scintigraphy and responsive-
ness to OCT, even in the presence of a high cortisol
level, can be explained by their relative resistance to
glucocorticoids, compared with corticotroph adenomas
(10). Additional in vitro evidence for a sst downregula-
tion by hypercortisolaemia comes from studies using
primary cultures of human corticotroph adenomas, in
which it was shown that glucocorticoids downregu-
lated the response of corticotrophin-releasing hormone
(CRH)-induced ACTH secretion to OCT (11). Little is
know yet about the quantitative expression levels of
the five sst subtypes (sst1 – 5) in normal and tumoral
corticotroph cells. By double-labelling in situ hybridiz-
ation analysis for sst2 and sst5 mRNA, Day et al. (12)
showed that normal rat corticotrophs expressed prefer-
entially sst5 mRNA. In a few selected cases expression
of sst subtype mRNA transcripts was studied in
human corticotroph adenomas. In these studies it
was found that the highest frequency of expression of
sst mRNA transcripts was found for sst2 and sst5, and
to a lesser extent sst1 (13 –16). Although sst2 mRNA
can be found in corticotroph adenomas, their levels of
expression are apparently low since OCT has no effect
on ACTH secretion in patients with pituitary-dependent
Cushing’s disease. However, at present the role of the
other frequently expressed sst subtype, sst5, on ACTH
secretion by corticotroph adenoma cells is unclear.
Recently, a novel multi-ligand SS analogue, SOM230,
has been synthesized. Compared with OCT, SOM230
has a 30-, 5- and 40-times higher binding affinity for
sst1, sst3 and sst5 receptors respectively, and 2.5-times
lower affinity for sst2 (17). The very high affinity of
this SS analogue for sst5 probably forms the basis for
the higher potency of SOM230 in reducing insulin-
like growth factor-I concentrations in rats, primates
and dogs (18). Moreover, the very favourable elimin-
ation half-life of SOM230, which is 23 h (17), makes
this novel compound suitable for clinical application
as well.
The present study was carried out to further explore
the potential functional significance of sst subtypes
expressed in human corticotroph adenomas. We evalu-
ated the effect of the SS analogue SOM230 on ACTH
secretion by primary cultures of human corticotroph
adenomas and mouse AtT20 corticotroph tumour cells.
Materials and methods
Patients
Pituitary tumour samples were obtained by transsphe-
noidal operation from 11 patients with Cushing’s dis-
ease due a corticotroph adenoma as described in
detail previously (19). ACTH-dependent hypercortiso-
lism was biochemically established by the absence of
cortisol diurnal rhythm, an increased 24 h free cortisol
excretion, insufficient suppression of plasma cortisol
concentrations after administration of 1 mg dexa-
methasone (DEX) and normal to increased plasma
ACTH concentrations. Magnetic resonance imaging of
the pituitary showed a microadenoma in seven
patients, a macroadenoma in one patient and no ade-
noma in three patients. In these latter patients, pitu-
itary ACTH overproduction was determined by sinus
petrosus inferior sampling. Histological examination
showed adenomatous tissue (n ¼ 9; case no. 1 and
nos 4–11) or hyperplasia (n ¼ 2; case nos 2 and 3)
with immunohistochemically expression of ACTH. All
patients gave their informed consent for the use of
tumour material for research purposes. After surgery,
7 of 11 patients were cured.
In six cases (nos 1–6) the tissue was directly snap-
frozen on dry ice and stored at 280 8C until analysis.
Adenoma tissue from the five additional patients (cul-
ture nos 7–11) was directly used for cell culturing.
Quantitative PCR
Quantitative PCR was performed as described pre-
viously (20). Briefly, poly Aþ mRNA was isolated from
adenoma tissue using Dynabeads Oligo (dT)25 (Dynal
AS, Oslo, Norway). cDNA was synthesized using the
poly Aþ mRNA, which was eluted from the beads in
40ml H2O for 2 min at 65 8C, using Oligo (dT)12 –18
Primer (Invitrogen). One-twentieth of the cDNA library
was used for quantification of sst subtype mRNA levels.
A quantitative PCR was performed by TaqMan Gold
nuclease assay (Perkin Elmer Corporation, Foster City,
CA, USA) and the ABI PRISM 7700 sequence Detection
System (Perkin Elmer, Groningen, The Netherlands) for
real-time amplifications, according to manufacturer’s
protocol. The assay was performed using 15ml
TaqMan Universal PCR Master Mix (Applied Biosys-
tems, Alphen a/d Ry¨n, The Netherlands), 500 nmol/l
forward primer, 500 nmol/l reverse primer,
100 nmol/l probe and 10ml cDNA template, in a total
reaction volume of 25ml. After an initial heating at
95 8C for 8 min, samples were subjected to 40 cycles
of denaturation at 95 8C for 15 s and annealing for
1 min at 60 8C. The primer and probe sequences that
were used are indicated below. The detection of hypox-
anthine-phosphoribosyl-transferase (HPRT) mRNA
served as a control and was used for normalization of
the sst subtype mRNA levels.
The primer and probe sequences that were used for
the detection of sst1, sst2, sst3, sst5 and HPRT mRNAs
have been described previously (20). In addition to
these primers and probes, we also evaluated sst4
mRNA expression in the present study using the
following primers and probe: sst4 forward 5
0-CTGCGCC-
AACCCTATTCTCT-30; sst4 reverse 50-ACCCGCTGGAAG-
GATCG-30; sst4 probe 50-FAM-TGGCTTCCTCTCCGACA-
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ACTTCCG-TAMRA-30. Primers and probes were pur-
chased from Biosource (Nivelles, Belgium).
The relative amount of sst subtype mRNA was deter-
mined using a standard curve generated from known
amounts of human genomic DNA. For determination
of the amount of HPRT mRNA, a standard curve was
generated of a pool of cDNAs from a human cell line
known to express HPRT. The relative amount of sst
subtype mRNA was calculated relative to the amount
of HPRT mRNA and is given in arbitrary units.
Each sample was assayed in duplicate. Poly Aþ
mRNA from AtT20/D16V cells was isolated as
described above. PCR analysis to determine the
expression of mouse sst1 – 5 mRNAs was performed as
described elsewhere (21).
Cell dispersion and cell culture
Pituitary adenoma tissue Single cell suspensions of
the pituitary adenoma tissues were prepared by enzy-
matic dissociation with dispase as described in detail
previously (19). For short-term incubation of mono-
layer cultures, the dissociated cells were plated in 48-
well plates (Corning BV Life Sciences, Schiphol-Rijk,
The Netherlands) at a density between 10 000 and
50 000 cells per well per 1 ml culture medium. After
3 –4 days the medium was changed and 4, 24 or
72 h incubations without or with test substances
were initiated. At the end of the incubation the
medium was collected and stored at 220 8C until hor-
mone determination. The cells were cultured at 37 8C in
a CO2 incubator. The culture medium consisted of Mini-
mum Essential Medium with Earle’s salts supplemented
with non-essential amino acids, sodium pyruvate
(1 mmol/l), 10% fetal calf serum (FCS), penicillin
(1 £ 105 U/l), Fungizone (0.5 mg/l), L-glutamine
(2 mmol/l), and sodium bicarbonate (2.2 g/l), pH 7.6.
Media and supplements were from Invitrogen. Unfortu-
nately, not enough tumour material was obtained to
test the adenoma cells at all time-points and the dose-
dependency of the effects by the indicated drugs.
Mouse corticotroph adenoma cells AtT20/D16V
mouse corticotroph tumour cells (Dr J Tooze, European
Organization for Molecular Biology) were routinely pas-
saged by trypsinization as described in detail previously
(22). The cells were maintained in 75 cm2 culture
flasks in Dulbecco’s Minimal Essential Medium, sup-
plemented with non-essential amino acids, sodium pyr-
uvate (1 mmol/l), 10% FCS, penicillin (1 £ 105 U/l),
Fungizone (0.5 mg/l), L-glutamine (2 mmol/l) and
sodium bicarbonate (2.2 g/l), pH 7.6. For experiments,
the cells were seeded at a density of 20 000 cells per
well in 1 ml of culture medium. After 72 h, the
medium was changed and 4, 24 or 72 h incubations
without or with OCT, SOM230 or SS-14 were initiated.
In addition, the acute effect of SS-14, OCT and SOM230
was evaluated in a 3 h incubation without or with
10 nmol/l CRH. In order to evaluate the effect of gluco-
corticoids on SS analogue-induced inhibition of ACTH
release, the cells were pre-treated in some experiments
for 48 h with the synthetic glucocorticoid DEX
(10 nmol/l). Thereafter, the medium was changed and
a 3 h incubation without or with OCT (1 nmol/l) or
SOM230 (1 nmol/l) in the presence of CRH
(10 nmol/l) was performed. After the indicated time
periods, the medium was collected and stored at
220 8C until determination of ACTH concentrations.
For determining the effects of the compounds on cell
growth, [3H]thymidine incorporation, as well as the
DNA content of the wells, was measured as described
in detail elsewhere (23).
Hormone determinations
Human ACTH concentrations were determined by a
non-isotopic, automatic chemiluminescence immu-
noassay system (Immulite; DPC Inc., Los Angeles, CA,
USA). Intra- and interassay coefficient of variation
(CV) values were 5.6 and 7.8% respectively. Human
growth hormone (GH), prolactin (PRL), luteinizing hor-
mone (LH) and follicle-stimulating hormone (FSH) con-
centrations in the media were determined, in order to
exclude the presence of contaminating normal pitu-
itary cells in the cultures. GH, PRL, LH and FSH con-
centrations were determined by a non-isotopic,
automatic chemiluminescence immunoassay system
as well (Immulite; DPC). Intra- and interassay CV
values for GH, PRL, LH and FSH were 6.0, 5.7, 5.7
and 6.4% and 6.2, 6.4, 12.3 and 7.5% respectively.
Except for the expected hormone ACTH, none of the
other hormones was detected (not shown).
Test substances
OCT (Sandostatin) was obtained from Novartis Pharma
AG (Basle, Switzerland). SOM230 was a gift from
Novartis Pharma AG. SS-14 was purchased from
Sigma Chemical Co. Binding affinities of SS-14, OCT
and SOM230 to the five sst subtypes are shown in
Table 1. DEX was obtained from the Erasmus MC Phar-
macy (Rotterdam, The Netherlands). CRH was pur-
chased from Ferring (Hoofddorp, The Netherlands).
Statistical analysis of the data
All data on hormone release are expressed as means^
S.E., n ¼ 4 wells per treatment group. All data were
analysed by ANOVA to determine overall differences
between treatment groups. When significant differ-
ences were found by ANOVA, a multiple comparison
between treatment groups was made using the
Newman –Keuls test. Calculation of IC50 values for
inhibition of hormone release were made using Graph-
Pad Prism (San Diego, CA, USA).
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Results
sst subtype mRNA expression
In six out six human corticotroph adenomas (nos 1 –6),
sst2 mRNA was detectable. However, the relative copy
numbers were low (varying between 8 and 141
copies/HPRT). The relative sst2 copy number was con-
siderably lower compared with the majority of GH-
secreting pituitary adenomas, as recently reported
(20). sst5 mRNA was detectable at much higher levels
in six out of six adenomas (relative copy number
between 277 and 1217). In the two cases in which his-
tological analysis of the tissue revealed hyperplasia of
ACTH-producing cells (case nos 2 and 3), sst5 mRNA
levels were relatively high. On the other hand, one
ACTH-secreting pituitary adenoma (case no. 1)
expressed the highest level of sst5 mRNA in the series.
sst1, sst3 and sst4 mRNA was detectable at low levels
in only one, two and two out of six samples respectively
(Fig. 1).
In agreement with the results of RT-PCR analysis of
the corticotroph adenomas, the sst subtype mRNAs
expressed in ACTH-secreting mouse AtT20 cortico-
troph pituitary tumour cells were sst2, sst3 (low abun-
dance) and sst5 (Fig. 2).
Effect of SS-14, OCT and SOM230 on basal
and CRH-induced ACTH secretion by primary
corticotroph adenoma cells
Since not sufficient tissue was obtained to carry out
both mRNA and culture studies on the same tissue,
cell culture experiments were performed using ade-
noma tissue from five additional patients (nos 7 –11).
In a 72 h incubation, SOM230 (10 nmol/l) significantly
suppressed ACTH secretion in three out of five primary
cultures of human corticotroph adenomas (between 30
and 40% suppression). In contrast, OCT (10 nmol/l)
suppressed basal ACTH release in only one out of five
cultures (28% suppression) (Fig. 3A and B). From one
corticotroph adenoma (no. 8) sufficient cells were
obtained to perform a time-course study of the effects
of SS-14, OCT and SOM230 on basal ACTH release.
As shown in Fig. 4A (4, 24 and 72 h incubation), stat-
istically significant (P , 0.01 vs untreated control
cells) suppression of ACTH release was observed only
after 72 h of incubation with SOM230 (10 nmol/l)
and SS-14 (10 nmol/l). Ten nmol/l of OCT did not
significantly inhibit basal ACTH release at any time-
point. A comparable time-course experiment was per-
formed in mouse AtT20 cells. In agreement with the
observations in primary human corticotroph adenoma
cultures, SOM230 and SS-14, but not OCT, all tested at
10 nmol/l, suppressed basal ACTH production (Fig. 4B).
The effect of SOM230 on basal ACTH release by AtT20
cells was dose-dependent with an IC50 value of
0.2 nmol/l (Fig. 5A), corresponding to the binding
affinity of SOM230 for sst5. In contrast, OCT inhibited
ACTH release with much lower potency with a slight
suppression at 100 nmol/l (Fig. 5A). Taken together,
these data suggest that the effect of SOM230 on basal
ACTH release is most probably mediated via sst5. OCT
and SOM230 did not inhibit AtT20 cell proliferation
as measured by [3H]thymidine incorporation (Fig. 5B),
and had no effect on the DNA content of the cells (not
shown).
In contrast to the absence of an effect of OCT on basal
ACTH release by AtT20 cells, OCT (10 nmol/l) signifi-
cantly suppressed CRH (10 nmol/l)-induced ACTH
release by 52% and SS-14 by 47% in a 3 h incubation.
SOM230 was significantly more potent and inhibited
CRH-induced ACTH release by 76% (Fig. 6). The
effect of SS-14 on CRH-induced ACTH-release by
AtT20 cells is in agreement with previous reports
(24 –26).
Effect of glucocorticoid pre-treatment
In order to evaluate whether pre-treatment of the cells
with glucocorticoids influenced the sensitivity to the
effects of OCT and SOM230, mouse AtT20 cells were
pre-treated with 10 nmol/l DEX during 48 h, after
which a 3 h incubation without or with CRH
(10 nmol/l), OCT (1 nmol/l) and/or SOM230
(1 nmol/l) was performed. Figure 7 shows that pre-
treatment of AtT20 cells with 10 nmol/l DEX had no
effect on the inhibitory effect of SOM230 on CRH-
induced ACTH release. On the other hand, the inhibi-
tory effect of 1 nmol/l OCT was completely abolished
by DEX pre-treatment. In the presence of DEX,
SOM230 almost completely abolished CRH-induced
ACTH release (Fig. 7, lower panel). Finally, DEX pre-
treatment did not change the inhibitory effects of
10 nmol/l OCT or SOM230 on CRH-induced ACTH
release (data not shown), suggesting that OCT at
10 nmol/l induced its inhibitory effect via interaction
with sst5, for which it has significantly lower affinity
Table 1 Binding affinity of SS-14, OCT and SOM230 for the five human sst subtypes, sst1–5. Data are reproduced with permission
from the society of the European Journal of Endocrinology (17). Results are mean^S.E. IC50 values (nmol/l).
Compound hsst 1 hsst 2 hsst 3 hsst 4 hsst 5
SS-14 0.93^0.12 0.15^0.02 0.56^0.17 1.5^0.4 0.29^0.04
OCT 280^80 0.38^0.08 7.1^1.4 .1000 6.3^1.0
SOM230 9.3^0.1 1.0^0.1 1.5^0.3 .100 0.16^0.01
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compared with SOM230 (Table 1). Moreover, in one
primary culture of corticotroph adenoma cells (case
no. 4), which was unresponsive to OCT, DEX
(10 nmol/l) pre-treatment did not reduce the inhibitory
effect by SOM230 on CRH (10 nmol/l)-induced ACTH
release as well (221% without DEX vs 233% in the
presence of DEX).
Discussion
Currently, there is no effective medical treatment option
in patients with pituitary-dependent Cushing’s disease
(3, 4). Therefore, in the present study we evaluated
the effects of the recently developed multi-ligand
stable SS analogue SOM230 (17, 18, 27), which has
high binding affinity to sst1, sst2, sst3 and sst5, on
ACTH release by human corticotroph tumours in vitro.
The role of SS in the regulation of normal ACTH
release is equivocal. Previous in vitro studies showed
no inhibitory effect of SS on basal and CRH-induced
ACTH release by normal rat anterior pituitary cells
(28) and perifused normal rat pituitary halves (29).
On the other hand, SS inhibited CRH-stimulated
ACTH release by fragments of pituitary glands (30),
as well as arginine vasopressin-induced ACTH release
by cultured pituitary cells from long-term adrenal-
ectomized rats (31). The latter study suggests that
normal corticotrophs only respond to SS in the pre-
sence of very low cortisol concentrations. Confirming
this hypothesis, we demonstrated that SS inhibits
CRH-stimulated ACTH secretion by normal rat anterior
pituitary cells only when the cells are cultured in the
absence of glucocorticoids in the culture medium
(32). In addition, pre-incubation of the cells with the
Figure 1 sst mRNA expression level in human corticotroph
adenomas. mRNA levels were determined by real-time PCR of
cDNA obtained from six human corticotroph adenomas (nos
1–6). Values are expressed as the number of copies relative to
HPRT mRNA.
Figure 2 Expression of sst subtypes in mouse AtT20 pituitary
tumour cells. Poly Aþ mRNA was reverse transcribed and cDNA
was amplified by PCR. PCR products of the sst1–5 were separ-
ated on 1% agarose gel and stained with ethidium bromide.
Upper panel represents cDNA synthesis in the presence of
reverse transcriptase (þRT); lower panel represents negative
control of cDNA synthesis in the absence of RT (2RT) to exclude
the presence of genomic DNA contamination. Only bands of sst2,
sst3 and sst5 PCR products with the expected molecular weight
(Mw) were detected.
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progesterone-glucocorticoid receptor-blocking com-
pound RU 38 486, increased the sensitivity of ACTH
secretion to the inhibitory effect by SS and pre-treat-
ment with DEX made the cells insensitive to SS (32).
The high levels of cortisol in patients with pituitary-
dependent Cushing’s disease can thus be responsible
for the observed lack of inhibition of ACTH release by
SS and/or OCT in these patients (6, 11, 33). Moreover,
in patients with Nelson syndrome and adrenal insuffi-
ciency of different origins, SS and/or OCT lower ACTH
secretion (6, 9, 34, 35). In cultured corticotroph ade-
nomas, SS and/or OCT inhibit ACTH secretion in part
of the cultures (11, 36–38). Stalla et al. (11) showed
that hydrocortisone treatment in vitro abolished the
inhibitory effect of OCT on ACTH secretion, possibly
due to a downregulation of sst on the corticotrophs.
In agreement with this hypothesis, cortisol reduced
[125I-Tyr1]SS binding on mouse AtT20/D16 pituitary
tumour cells by 20–40% (39), although the sst subtype
was not characterized.
Little is known with respect to sst subtype expression
in pituitary corticotrophs. In rat pituitary cells, co-local-
ization of all five sst subtypes with ACTH-expressing cells
has been reported (40). In another study, sst5 mRNA was
found in 38% of normal corticotrophs, and sst2 in only
3%. Moreover, the average number of grains per cell
was also higher for sst5 than sst2 (12). This suggests
that under normal physiological conditions, sst5 is pre-
dominantly more expressed in rat corticotrophs than
sst2. As far as is known, no data on the quantitative
expression of sst mRNA in human corticotroph adeno-
mas are available. In the present study we found that
at the mRNA level, sst5 was the predominantly expressed
receptor type in human corticotroph adenomas. In the
small series of tissues (n ¼ 6) analysed in this study,
two cases of hyperplasia of corticotroph cells expressed
a relatively high sst5 mRNA level. On the other hand,
one corticotroph adenoma expressed the highest sst5
mRNA level in this series. The number of cases is too
low, however, to establish whether there is a difference
in sst5 mRNA expression between hyperplasia of
ACTH-producing cells and ACTH-secreting adenoma.
sst2 mRNA was expressed in all cases as well, although
at a much lower level. The high frequency of expression
of sst2 and sst5 in corticotroph adenomas is well in agree-
ment with other reports. mRNA expression in human
corticotroph tumours shows the overall presence of
sst1 in five out of eight (63%), sst2 in seven out of eight
(88%), sst3 in three out of nine (33%), sst4 in one out
of eight (12%), and sst5 in six out of seven (86%) cases
(13 –15, 41, 42). The low expression levels of sst2 may
explain the lack of efficacy of the sst2-preferring agonist
OCT in lowering circulating ACTH and cortisol levels in
untreated patients with pituitary-dependent Cushing’s
disease (6, 11). In vitro we found a statistically significant
inhibition of basal ACTH release by OCT in only one out
of five cases. The higher number of cultures (three out of
five) responding to a maximally active concentration of
10 nmol/l SOM230, which has very high binding affi-
nity for sst5, is in agreement with the higher expression
levels of sst5 mRNA. Unfortunately, not enough tissue
was obtained to perform both mRNA analysis and cell
culture studies. In one adenoma, which had an inter-
mediate sst5 mRNA level (case no. 4), SOM230 already
inhibited ACTH secretion, whereas OCT had no effect.
It should be noted that only mRNA levels were studied.
Future studies should demonstrate whether sst5 recep-
tors are expressed in corticotroph adenomas at a high
protein level as well. The importance of sst5 in regulating
ACTH release was further confirmed by our observation
that SOM230 was also much more potent compared
with OCT in inhibiting basal ACTH release by mouse
AtT20/D16V corticotroph tumour cells. The pattern of
inhibition, e.g. a higher potency of SOM230 vs OCT, is
Figure 3 Effect of 10 nmol/l OCT (A) and 10 nmol/l SOM230 (B)
on basal ACTH release from five cultured human corticotroph
adenomas (nos 7–11). The cells were incubated in the absence
or presence of OCT (A) or SOM230 (B) during 72 h after which
the medium was collected for ACTH determination. Values are
expressed as per cent of control (CON; untreated cells). Basal
ACTH concentrations in the culture media were 239^5.0,
28 800^1159, 25 100^2150, 218^12 and 3228^153 fmol/well,
for cultured adenomas nos 7, 8, 9, 10 and 11 respectively.
*P , 0.05 and **P , 0.01 vs control. Means^S.E., n ¼ 4 wells per
treatment group.
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in line with the sst binding profile of both SS analogues.
Recently, Cervia et al. (43) showed that sst2 is the predo-
minant functional receptor subtype in AtT20 cells, while
sst5 is also able to mediate inhibition of ACTH release
when the ligand is not able to activate sst2 receptors.
Interestingly, while SOM230 was much more potent in
inhibiting basal ACTH release by AtT20 cells, we
found that OCT also potently inhibited CRH-induced
ACTH release. However, maximal inhibition of ACTH
by SOM230 was significantly higher compared with
OCT. These data suggest that expression of sst2 in our
AtT20 line is relatively low, compared with sst5. The
involvement of both sst2 and sst5 in the regulation of
ACTH release is further underlined by the observation
that sst2- and sst5-specific agonists potently inhibit
ACTH release and cAMP production by AtT20 cells (44).
As indicated above, glucocorticoids may downregu-
late sst on AtT20 corticotrophs and lower responsive-
ness of ACTH to the inhibitory effect of SS and/or
OCT. Therefore, we also studied whether pre-treatment
of the cells with the synthetic glucocorticoid DEX
(10 nmol/l) reduced responsiveness of the cells to inhi-
bition of ACTH release by SOM230. We found that glu-
cocorticoid pre-treatment did not influence the
inhibitory effect of SOM230 on CRH-induced ACTH
release, suggesting that the expression of functional
sst5 receptors is relatively resistant to glucocorticoids.
This may also explain the higher expression levels of
sst5 mRNA we found in human corticotroph adenomas
from untreated patients with pituitary-dependent Cush-
ing’s disease. These data suggest that glucocorticoids
may have differential regulatory effects on sst2 and
sst5 expression. An intriguing observation is that
SOM230 and SS-14 only inhibit basal ACTH secretion
after prolonged in vitro exposure. SOM230 did not inhi-
bit AtT20 cell proliferation. Therefore, other mechan-
isms, e.g. inhibition of pro-opiomelanocortin synthesis
and/or increased ACTH breakdown, as has been
shown for the effect of OCT on GH-secreting pituitary
adenomas (45, 46), may form additional explanations
for the inhibitory effect of SOM230 and SS-14 on
basal ACTH secretion. Interestingly, recent evidence
suggests that sst5 is also important in the control of
ACTH secretion in vivo. sst5 knock-out mice were
shown to have significantly elevated ACTH and corti-
costerone levels, compared with wild-type mice (47).
While our data suggest that the novel SS analogue
SOM230 may be useful in the medical management of
Figure 4 Time-dependent effect of OCT (10 nmol/l), SOM230 (10 nmol/l) and SS-14 (10 nmol/l) on basal ACTH release from cultured
human corticotroph adenoma no. 8 (A) and mouse AtT20 corticotroph tumour (B) cells. The cells were incubated for 4, 24 or 72 h in the
absence or presence of the indicated compounds, after which medium was collected for ACTH determination. Values are expressed as
the per cent of ACTH release by control (untreated) cells at the indicated time-points. For the human corticotroph adenoma cells, basal
ACTH values were 3505^232 (4 h), 9778^946 (24 h) and 28 800^1159 (72 h) fmol/well. *P , 0.01 vs control. Means^S.E., n ¼ 4 wells
per treatment group.
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patients with pituitary-dependent Cushing’s disease,
several issues will have to be clarified. First, prolonged
treatment of AtT20 cells with SS-14 results in desensit-
ization of its inhibitory effect on ACTH secretion and
cAMP formation (48, 49). In addition, prolonged agonist
exposure of AtT20 cells with SS-14 or SS-28 was shown
to downregulate SS-14 receptors (50). However, these
studies only evaluated the acute inhibitory effects of
SS-14 on AtT20 cells. Moreover, the effects of SOM230
are most likely sst5-mediated and sst5 receptors have
shown to be rapidly recycled and recruited from intra-
cellular storages after agonist activation. This combi-
nation of recycling and recruitment of spare sst5
receptors may protect from long-term downregulation
through sequestration and, therefore, facilitate extended
SS signalling (51). We observed that the inhibitory
effects of SOM230 on basal ACTH secretion became
only apparent after prolonged exposure. This obser-
vation already suggests that endogenously expressed
sst5 receptors may be more resistant to desensitization
and/or downregulation. Nevertheless, the in vivo effect
of SOM230 on ACTH secretion by corticotroph adeno-
mas needs to be further evaluated.
In conclusion, the selective expression of sst5 recep-
tors in human corticotroph adenomas, in combination
with the inhibitory effect of SOM230 on basal and
CRH-induced ACTH secretion, suggests that SOM230
may have potential in the medical treatment of pitu-
itary-dependent Cushing’s disease.
Figure 5 Dose-dependent effect of SOM230 and OCT on basal
ACTH release (A) and cell proliferation as measured by [3H]thymi-
dine incorporation (B) by mouse AtT20 pituitary tumour cells.
AtT20 cells were incubated during 72 h without or with increasing
concentrations of OCT (W) or SOM230 (X), after which the medium
was collected for ACTH determination. Values are expressed as
the per cent of control (untreated) cells. *P , 0.05 and **P , 0.01
vs control. Means^S.E., n ¼ 4 wells per treatment group.
Figure 6 Effect of OCT, SS-14 and SOM230 on CRH-stimulated
ACTH release by mouse AtT20 pituitary tumour cells. AtT20 cells
were incubated for 3 h in the absence or presence of CRH together
with either SS-14, OCT or SOM230, after which the medium was
collected for ACTH determination. Values are expressed as the per
cent of control (untreated) cells. *P , 0.01 vs control,
#P , 0.01 vs
CRH alone. Means^S.E., n ¼ 4 wells per treatment group.
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